You are here
Spherix Notes Additional Patent Coverage Granted
NEW YORK, Nov. 27, 2019 /PRNewswire/ -- Spherix Incorporated (Nasdaq: SPEX) announced today that additional patent coverage has been granted by the United States Patent & Trademark Office to the patent portfolio being acquired by Spherix, in the field of pancreatic cancer.
Pancreatic cancer is the fourth most common cause of cancer-related deaths in the United States and the eighth worldwide. The Pancreatic Cancer Action Network Ô predicted that it will move from fourth to the second leading cause of cancer deaths in the US by 2020. US Patent number 10,463,684 was recently issued to the University of Texas at Austin and being assigned to Spherix as part of the CBM BioPharma, Inc. asset acquisition previously announced. The patent targets, among other things, pancreatic cancer with a different mechanism than the current standard of care. The compound has been shown to be effective in cancer cells that are resistant to the current standard of care in preclinical studies and expands the patent coverage for this compound.
Spherix Incorporated is a technology development company committed to the fostering of innovative ideas. Spherix Incorporated was formed in 1967 as a scientific research company.
Certain statements made herein are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as "may", "should", "would", "plan", "intend", "anticipate", "believe", "estimate", "predict", "potential", "seem", "seek", "continue", "future", "will", "expect", "outlook" or other similar words, phrases or expressions. These forward-looking statements include statements regarding Spherix's and CBM's industry, future events, the proposed transaction between the parties to the Asset Purchase Agreement, the estimated or anticipated future results and benefits of the Company following the transaction, including the likelihood and ability of the parties to successfully consummate the proposed transaction, future opportunities for the combined company, and other statements that are not historical facts. These statements are based on the current expectations of Spherix's management and are not predictions of actual performance. These statements are subject to a number of risks and uncertainties regarding the businesses of Spherix and the transaction, and actual results may differ materially. These risks and uncertainties include, but are not limited to, changes in the business environment in which Spherix or CBM operates, including inflation and interest rates, and general financial, economic, regulatory and political conditions affecting the industry in which Spherix or CBM operates; changes in taxes, governmental laws, and regulations; competitive product and pricing activity; difficulties of managing growth profitably; the inability of the parties to successfully or timely consummate the proposed transaction, including the risk that any required regulatory approvals are not obtained, are delayed or are subject to unanticipated conditions that could adversely affect the combined company or the expected benefits of the transaction; failure to realize the anticipated benefits of the transaction, including as a result of a delay in consummating the transaction or a delay or difficulty in integrating the assets of CBM; uncertainty as to the long-term value of Spherix's common stock; those discussed in the Spherix's Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q and other documents of Spherix on file with the SEC or in the registration statement that will be filed with the SEC by Spherix. There may be additional risks that Spherix presently does not know or that Spherix currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements provide Spherix's expectations, plans or forecasts of future events and views as of the date of this communication. Spherix anticipates that subsequent events and developments will cause Spherix's assessments to change. However, while Spherix may elect to update these forward- looking statements at some point in the future, Spherix specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Spherix's assessments as of any date subsequent to the date of this communication.
Brett Maas, Managing Partner
Phone: (646) 536-7331
View original content to download multimedia:http://www.prnewswire.com/news-releases/spherix-notes-additional-patent-coverage-granted-300966329.html
SOURCE Spherix Incorporated